Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells

27 Nov 2019

Abstract excerpt

Lung cancer patients face a dismal prognosis mainly due to the low efficacy of current available treatments. Cisplatin is the first-line chemotherapy treatment for those patients, however, resistance to this drug is a common and yet not fully understood phenomenon. Aiming to shed new light into this puzzle, we used established normal and malignant lung cell lines displaying different sensitivity towards cisplatin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy-induced organ toxicity mitigation
Share to Genomics, phytochemicals, and oxidative stress
Share to Glutathione Transferases and Polymorphisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31776385
DOI: 10.1038/s41598-019-54065-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cellsPMID 31776385Read ↗

Aberrant ROS Served as an Acquired Vulnerability of Cisplatin-resistant Lung CancerSemantic proximity Read ↗

Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.Semantic proximity Read ↗

DNA Damage Response Network and Intracellular Redox Status in the Clinical Outcome of Lung Cancer PatientsSemantic proximity Read ↗

Characterization of the nucleotide excision repair pathway and evaluation of compounds for overcoming the cisplatin resistance of non‑small cell lung cancer cell linesSemantic proximity Read ↗

RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.Semantic proximity Read ↗

KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?Semantic proximity Read ↗

Distinct mechanisms by which antioxidant transcription factors Nrf1 and Nrf2 as drug targets contribute to the anticancer efficacy of Cisplatin on hepatoma cellsSemantic proximity Read ↗

Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.Semantic proximity Read ↗

Antioxidant induces DNA damage, cell death and mutagenicity in human lung and skin normal cells.Semantic proximity Read ↗

Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapySemantic proximity Read ↗

[Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations].Semantic proximity Read ↗

Vulnerability of Antioxidant Drug Therapies on Targeting Nrf2-Trp53-Jdp2 Axis in Controlling the TumorigenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.